Predictive Factors of Response to Immunotherapy in Lymphomas : A Multicentre Clinical Data Warehouse Study (PRONOSTIM)
Immunotherapy (IT) is a major therapeutic strategy for lymphoma, significantly improving patient prognosis. IT remains ineffective for a significant number of patients, however, and exposes them to specific toxicities. The identification predictive factors around efficacy and toxicity would allow better targeting of patients with a higher ratio of benefit to risk. PRONOSTIM is a multicenter and retrospective study using the Clinical Data Warehouse (CDW) of the Greater Paris University Hospitals network. Adult patients with Hodgkin lymphoma or diffuse large-cell B lymphoma treated with immune checkpoint inhibitors or CAR T (Chimeric antigen receptor T) cells between 2017 and 2022 were included. Analysis of covariates influencing progression-free survival (PFS) or the occurrence of grade ≥3 toxicity was performed. In total, 249 patients were included. From this study, already known predictors for response or toxicity of CAR T cells such as age, elevated lactate dehydrogenase, and elevated C-Reactive Protein at the time of infusion were confirmed. In addition, male gender, low hemoglobin, and hypo- or hyperkalemia were demonstrated to be potential predictive factors for progression after CAR T cell therapy. These findings prove the attractiveness of CDW in generating real-world data, and show its essential contribution to identifying new predictors for decision support before starting IT.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Cancers - 15(2023), 16 vom: 09. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Detroit, Marion [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical data warehouse |
|---|
| Anmerkungen: |
Date Revised 28.08.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers15164028 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361252374 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361252374 | ||
| 003 | DE-627 | ||
| 005 | 20231226084742.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers15164028 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361252374 | ||
| 035 | |a (NLM)37627056 | ||
| 035 | |a (PII)4028 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Detroit, Marion |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Predictive Factors of Response to Immunotherapy in Lymphomas |b A Multicentre Clinical Data Warehouse Study (PRONOSTIM) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.08.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Immunotherapy (IT) is a major therapeutic strategy for lymphoma, significantly improving patient prognosis. IT remains ineffective for a significant number of patients, however, and exposes them to specific toxicities. The identification predictive factors around efficacy and toxicity would allow better targeting of patients with a higher ratio of benefit to risk. PRONOSTIM is a multicenter and retrospective study using the Clinical Data Warehouse (CDW) of the Greater Paris University Hospitals network. Adult patients with Hodgkin lymphoma or diffuse large-cell B lymphoma treated with immune checkpoint inhibitors or CAR T (Chimeric antigen receptor T) cells between 2017 and 2022 were included. Analysis of covariates influencing progression-free survival (PFS) or the occurrence of grade ≥3 toxicity was performed. In total, 249 patients were included. From this study, already known predictors for response or toxicity of CAR T cells such as age, elevated lactate dehydrogenase, and elevated C-Reactive Protein at the time of infusion were confirmed. In addition, male gender, low hemoglobin, and hypo- or hyperkalemia were demonstrated to be potential predictive factors for progression after CAR T cell therapy. These findings prove the attractiveness of CDW in generating real-world data, and show its essential contribution to identifying new predictors for decision support before starting IT | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a clinical data warehouse | |
| 650 | 4 | |a lymphoma | |
| 650 | 4 | |a predictive factors of immunotherapy | |
| 650 | 4 | |a real-world data | |
| 700 | 1 | |a Collier, Mathis |e verfasserin |4 aut | |
| 700 | 1 | |a Beeker, Nathanaël |e verfasserin |4 aut | |
| 700 | 1 | |a Willems, Lise |e verfasserin |4 aut | |
| 700 | 1 | |a Decroocq, Justine |e verfasserin |4 aut | |
| 700 | 1 | |a Deau-Fischer, Bénédicte |e verfasserin |4 aut | |
| 700 | 1 | |a Vignon, Marguerite |e verfasserin |4 aut | |
| 700 | 1 | |a Birsen, Rudy |e verfasserin |4 aut | |
| 700 | 1 | |a Moufle, Frederique |e verfasserin |4 aut | |
| 700 | 1 | |a Leclaire, Clément |e verfasserin |4 aut | |
| 700 | 1 | |a Balladur, Elisabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Deschamps, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Chauchet, Adrien |e verfasserin |4 aut | |
| 700 | 1 | |a Batista, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Limat, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Treluyer, Jean-Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Ricard, Laure |e verfasserin |4 aut | |
| 700 | 1 | |a Stocker, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Hermine, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Choquet, Sylvain |e verfasserin |4 aut | |
| 700 | 1 | |a Morel, Véronique |e verfasserin |4 aut | |
| 700 | 1 | |a Metz, Carole |e verfasserin |4 aut | |
| 700 | 1 | |a Bouscary, Didier |e verfasserin |4 aut | |
| 700 | 1 | |a Kroemer, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Zerbit, Jérémie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 15(2023), 16 vom: 09. Aug. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:16 |g day:09 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers15164028 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 16 |b 09 |c 08 | ||